Skip to main content

Table 1 Study population characteristics according to presence of  ≥ 10 infiltrating ARG1-positive cells per 1 mm tissue core.

From: Discovery of a new marker to identify myeloid cells associated with metastatic breast tumours

 

Study population

Infiltration of ≥ 10 ARG1-positive  cells

No

Yes

p-value (χ2)

N (%)

487

454 (93)

33 (7)

 

Mean age at diagnosis, years (SD)

75.8 (8.5)

75.9 (8.5)

74.6 (9.1)

 

Mean follow-up after diagnosis, years (SD)

9.1 (7.0)

9.2 (7.0)

8.3 (8.1)

 

Deaths from BC (%)

166 (34)

152 (33)

14 (42)

 

Deaths from other causes (%)

274 (56)

260 (57)

14 (42)

 

Grade (%)

 I

54 (11)

52 (11)

2 (6)

0.005

 II

277 (57)

265 (59)

12 (36)

 

 III

155 (32)

136 (30)

19 (58)

 

Lymph node metastasis (%)

 Yes

167 (34)

154 (34)

13 (39)

0.2

 No

218 (45)

208 (46)

10 (30)

 

 Unknown histology

102 (21)

92 (20)

10 (30)

 

Molecular type (%)

 Luminal A

259 (53)

247 (55)

12 (36)

 < 0.001

 Luminal B (HER2)

115 (24)

11 (24)

5 (15)

 

Luminal B (HER2+)

36 (7)

34 (8)

2 (6)

 

 HER2 type

27 (6)

21 (5)

6 (18)

 

 5NP

12 (2)

11 (2)

1 (3)

 

 BP

36 (7)

29 (6)

7 (21)

 

Histologic subtype (%)

 Ductal (NOS)

341 (70)

321 (71)

20 (61)

0.03

 Lobular

63 (13)

61 (13)

2 (6)

 

 Other

83 (17)

72 (16)

11 (33)

 

ER status (%)

 < 1

70 (14)

58 (13)

12 (36)

0.004

 ≥ 1, < 10

17 (3)

15 (3)

2 (6)

 

 ≥ 10, < 50

22 (5)

20 (4)

2 (6)

 

 ≥ 50, < 90

63 (13)

58 (13)

5 (15)

 

 ≥ 90

313 (64)

301 (66)

12 (36)

 

 Unknown

2 (0)

2 (0)

0 (0)

 

Ki67 high/low (%)

 Ki67 < 15%

293 (60)

280 (62)

13 (39)

0.04

 Ki67 ≥ 15%

192 (39)

172 (38)

20 (61)

 

 Mitoses/10 HPF, median (IQR p25, p75)

5 (1, 12)

5 (1, 1)

12 (4, 20)

 

Mitoses/10 HPF, quartiles (%)

 ≤ 1 cm

128 (26)

123 (27)

5 (15)

 < 0.001

 > 1, ≤ 5

131 (27)

126 (28)

5 (15)

 

 > 5, ≤ 12

117 (24)

107 (24)

10 (30)

 

 > 12

111 (23)

98 (22)

13 (39)

 
  1. N, number of patients; SD, standard deviation; BC, breast cancer; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; 5NP, 5 negative phenotypes; BP, basal phenotype; HPF, high-power field; IQR, interquartile range